Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden on cytological samples: A pilot study.

Cancer cytopathology - 1 Jun 2021

Pepe Francesco, Pisapia Pasquale, Gristina Valerio, Rocco Danilo, Micheli Mariacarolina, Micheli Pietro, Iaccarino Antonino, Tufano Rossella, Gragnano Gianluca, Russo Gianluca, De Luca Caterina, Sgariglia Roberta, Nacchio Mariantonia, Girolami Ilaria, Eccher Albino, Russo Antonio, Troncone Giancarlo, Malapelle Umberto

Abstract excerpt

BACKGROUND: Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytological Techniques

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Pilot Projects

Share to Prognosis

Source

Identifiers

PMID: 33378102
DOI: 10.1002/cncy.22400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden on cytological samples: A pilot study.PMID 33378102Read ↗

Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.Semantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and cliniciansSemantic proximity Read ↗

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.Semantic proximity Read ↗

Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel AssaySemantic proximity Read ↗

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panelsSemantic proximity Read ↗

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.Semantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.Semantic proximity Read ↗

The emerging development of tumor mutational burden in patients with NSCLC.Semantic proximity Read ↗

The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.Semantic proximity Read ↗

Consistency and reproducibility of next‐generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.